PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
PD-1 and PD-L1 are differentially expressed in oncogene-addicted NSCLC supporting further investigation of specific checkpoint inhibitors in combination with targeted therapies.